bioRxivMicrobiologyPreprint
Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.
A. Dabrowska, A. Szczepanski, P. Botwina, N. Mazur-Panasiuk, H. Jirincova, L. Rabalski, T. Zajic, G. Popowicz, K. Pyrc
Abstract
The Omicron variant of the SARS-CoV-2 virus was first detected in South Africa in November 2021. The analysis of the sequence data in the context of earlier variants suggested that it may show very different characteristics, including immune evasion and increased transmission. These assumptions were partially confirmed, and the reduction in protection in convalescent patients and vaccinated individuals have been confirmed. Here, we have evaluated the efficacy of antivirals against SARS-CoV-2 variants, Omicron, Delta, and the early 2020 isolate.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Reduced infectivity but increased immune escape of the new SARS-CoV-2 variant of concern Omicron
J. Hu, P. Peng, … A.-l. Huang·bioRxiv·Dec 24, 2021
- Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
H. Ohashi, T. Hishiki, … K. Watashi·bioRxiv·Feb 27, 2022
- Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
D. Planas, N. Saunders, … O. Schwartz·bioRxiv·Dec 14, 2021
- Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant
R. Rosales, B. L. McGovern, … K. M. White·bioRxiv·Jan 17, 2022
- Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants
A. Banerjee, J. Lew, … D. Falzarano·bioRxiv·Jan 13, 2022
- Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
L. Liu, S. Iketani, … D. D. Ho·bioRxiv·Dec 14, 2021